The effect of polymorphisms of MTHER gene and vitamin B on hyperhomocysteinemia

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 21, Issue 1, 2001, Pages 17-20

  Chen, Jian ^a   Zhang, Jinzhi ^a   Cheng, Longxian ^a   Li, Yushu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Coronary artery disease; Folate; Gene; Hyperhomocysteinemia; Vitamin B12

Indexed keywords

DISEASES; ENZYMES; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MUTAGENESIS; PATIENT MONITORING; VITAMINS;

CORONARY ARTERY DISEASE; FOLATE; HYPERHOMOCYSTEINEMIA; VITAMIN B12;

GENES;

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADULT; AGED; ARTICLE; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; GENETICS; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; METABOLISM; POINT MUTATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; CORONARY ARTERIOSCLEROSIS; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POINT MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; VITAMIN B 12;

EID: 24944577884     PISSN: 0257716X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02888026     Document Type: Review

References (17)

1. Stampfer M J, Malinow M R, Willett W C et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA, 1992, 268 (7): 881
2. Girelli B D, Friso S, Trabetti E et al. Methylenetetrahydrofolate reductase C677 T mutation, plasma homocysteine, and folate in subjects from Northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood, 1998, 91 (11): 4158
3. Kang S S, Passen E L, Ruggie N et al. Thermolabile defect of methylenete-trahydrofolate reductase in coronary artery disease. Circulation, 1993, 88: 1463
4. Frosst P, Blam H J, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet, 1995, 10: 111
5. Verhoeff B J, Trip M D, Prins M H et al. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. Atherosclerosis, 1998, 141: 161
6. Vester B, Rasmussen K. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem, 1991, 29: 549
7. Soriente L, Coppola A, Madonna P et al. Homozygous C677 T mutation of the 5, 10-methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in Italian patients with a history of early-onset ischemic stroke. Stroke, 1998, 29(4): 869
8. Deloughery T G, Evans A, Sadeghi A et al. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. Circulation, 1996, 94(12): 3074
9. Lentz S R. Homocysteine and vascular disfunction. Review. Life Science, 1997, 61: 1205
10. Tsai J C, Perrella M A, Yoshizumi M et al. Promotion of vascular smooth muscle cell growth by homocysteime: a link to atherosclerosis. Proc Natl Acad Sci USA, 1994, 91: 6369
11. Harpel P C, Zhang X X, Borth W. Homocysteine and hemostasis: pathogenetic mechanisms predisposing to thrombosis. J Nutr, 1996, 126(4 suppl): 1285s
12. Liao J K, Shin W S, Lee W Y. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem, 1995, 270: 319
13. Harpel P C, Chang V T, Borth W. Homocysteine and other sulphydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogenesis and sulphydryl compound metabolism. Proc Natl Acad Sci USA, 1989, 10: 193
14. Koch H G, Goebeler M, Marquardt T et al. The redox status of aminothiols as a clue to homocysteine-induced vascular damage? Eur J Pediatr, 1998, 157 (suppl 2): S102
15. Boers G. Moderate hyperhomocysteineamia and vascular disease: evidence, relevance and the effect of treatment. Eur J Pediatr, 1998, 157 (suppl 2): S127
16. Kluijtmans L A J, Kastelein J J P, Lindemans J et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation, 1997, 96(8): 573
17. Morita H, Taguchi J, Kurihara H et al. Genetic polymorphism of 5, 10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation, 1997, 95 (8): 2032